Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 32Recurrence 8Neoplasms 6Neoplasms, Plasma Cell 5Waldenstrom Macroglobulinemia 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Diseases 2Smoldering Multiple Myeloma 1Sarcoma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Carcinoma, Small Cell 1Blood Protein Disorders 1Amyloidosis 1

Interventions

Dexamethasone 2Calcium Dobesilate 2Bortezomib 2pomalidomide 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1atezolizumab 1Transplantation, Autologous 1Melphalan 1Lenalidomide 1Gene Expression Profiling 1Fatty Acids, Omega-3 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Smoldering Multiple Myeloma × pomalidomide × Clear all
NCT05288062 2025-08-20

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Mayo Clinic

Phase 2 Terminated
17 enrolled 9 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡